Overall Survival – Secondary Endpoint

For first-line treatment of adult patients with locally advanced or metastatic EGFR+ NSCLC

Unmatched survival: RYBREVANT® + LAZCLUZE® delivers superior overall survival vs osimertinib with proven durability1,2

RYBREVANT® + LAZCLUZE® overall survival graph RYBREVANT® + LAZCLUZE® overall survival graph

Median overall survival not reached with RYBREVANT® + LAZCLUZE® and projected to exceed 4
years1,3

Based on modeling using observed HR and mOS in the osimertinib group, assuming exponential distribution of OS in both arms. The baseline factors were: mutation type, race, brain metastases, age, sex, ECOG PS, and weight. This is a conservative estimate; final results may vary.3

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; HR, hazard ratio; mNSCLC, metastatic non–small cell lung cancer; mOS, median overall survival; NE, not estimable; NSCLC, non–small cell lung cancer; OS, overall survival.

Progression-Free Survival – Primary Endpoint

For first-line treatment of adult patients with locally advanced or metastatic EGFR+ NSCLC

Superior PFS vs osimertinib with a chemo-free combination1,4

RYBREVANT® + LAZCLUZE® demonstrated a statistically significant reduction in the risk of progression or death by 30% vs osimertinib1,5

RYBREVANT® + LAZCLUZE® reduction in the risk of progression or death by 30% vs osimertinib graph RYBREVANT® + LAZCLUZE® reduction in the risk of progression or death by 30% vs osimertinib graph

7.1-month improvement in mPFS vs osimertinib1

  • 23.7-month (95% CI: 19.1, 27.7) mPFS with RYBREVANT® + LAZCLUZE® vs 16.6-month (95% CI: 14.8, 18.5) mPFS with osimertinib
In the non-registrational LAZCLUZE® arm, mPFS was 18.5 months (95% CI: 14.8, 20.1).5
MARIPOSA study design

NCCN PREFERRED FIRST-LINE
THERAPY*

First-line amivantamab† (RYBREVANT FASPRO™ or RYBREVANT®) + lazertinib (LAZCLUZE®) is the only NCCN Category 1 preferred multitargeted treatment option for patients with EGFR+‡ mNSCLC according to the National Comprehensive Cancer Network® (NCCN®).6§||

*EGFR mutation discovered prior to first-line systemic therapy.6

†Amivantamab includes both amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO™) subcutaneous injection and IV amivantamb-vmjw (RYBREVANT®). Amivantamab and hyaluronidase-lpuj has different dosing and administration instructions compared with IV amivantamab-vmjw.6

‡EGFR exon 19 deletion or exon 21 L858R mutations.6

§See the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for detailed recommendations, including other treatment options.

||Prophylactic anticoagulation is recommended at the time of initiation to prevent venous thromboembolic events.6

PFS results in prespecified subgroups5

PFS results in prespecified subgroups chartPFS results in prespecified subgroups chart

MARIPOSA: The largest phase 3 trial of 1L EGFR+ disease, with ~90% of patients having at least 1 high-risk feature5,7-18

Pathogenic alterations (N=636) were identified by NGS using ctDNA from blood with Guardant360 CDx at baseline18

54% TP53 co-mutations image
(N=149 in RYBREVANT® + LAZCLUZE® arm; N=144 in osimertinib arm)5,18

Other common high-risk features included5,18:

41%

brain metastases

(RYBREVANT® + LAZCLUZE® N=178, osimertinib N=172)

16%

liver metastases

(RYBREVANT® + LAZCLUZE® N=64, osimertinib N=72)

85%

detectable ctDNA

(RYBREVANT® + LAZCLUZE® N=231, osimertinib N=240)

Prevalences of high-risk features in this analysis were consistent with previously reported rates.18-22

PFS results for patients with biomarkers of high-risk disease5,18,23

Brain metastases
Liver metastases
TP53 co-mutation
ctDNA by ddPCR†
RYBREVANT®
+ LAZCLUZE®
(N=178)
Osimertinib
(N=172)
RYBREVANT®
+ LAZCLUZE®
(N=64)
Osimertinib
(N=72)
RYBREVANT®
+ LAZCLUZE®
(N=149)
Osimertinib
(N=144)
RYBREVANT®
+ LAZCLUZE®
(N=231)
Osimertinib
(N=240)
mPFS, months (95% CI)18.3
(16.6, 23.7)		13
(12.2, 16.4)		18.2
(13.1, NE)		11
(7.4, 12.8)		18.2
(15.3, 22.1)		12.9
(11.1, 14.7)		20.3
(16.6, 24)		14.8
(12.9, 16.5)
HR (95% CI)0.69
(0.53, 0.92)		0.58
(0.37, 0.91)		0.65
(0.48, 0.87)		0.68
(0.53, 0.86)
Reduction in risk of
progression or death		31%42%35%32%
Brain metastases
RYBREVANT®
+ LAZCLUZE®
(N=178)		18.3
(16.6, 23.7)		0.69
(0.53, 0.92)		31%
Osimertinib
(N=172)		13
(12.2, 16.4)
Liver metastases
RYBREVANT®
+ LAZCLUZE®
(N=64)		18.2
(13.1, NE)		0.58
(0.37, 0.91)		42%
Osimertinib
(N=72)		11
(7.4, 12.8)
TP53 co-mutation
RYBREVANT®
+ LAZCLUZE®
(N=149)		18.2
(15.3, 22.1)		0.65
(0.48, 0.87)		35%
Osimertinib
(N=144)		12.9
(11.1, 14.7)
ctDNA by ddPCR†
RYBREVANT®
+ LAZCLUZE®
(N=231)		20.3
(16.6, 24)		0.68
(0.53, 0.86)		32%
Osimertinib
(N=240)		14.8
(12.9, 16.5)

This analysis is not included in the Prescribing Information for RYBREVANT® or LAZCLUZE®. This was a post hoc exploratory analysis and was not powered to show statistical significance.
*In MARIPOSA, pathogenic alterations were identified by NGS using ctDNA from blood with Guardant360 CDx at baseline. Ex19del and L858R ctDNA in blood was analyzed at baseline with Biodesix ddPCR. This exploratory analysis included all randomized patients who had 1 or more biomarker assessments. Subgroup analyses of efficacy endpoints were carried out using statistical methods for the primary analysis of the general MARIPOSA population.18
†Consistent results were seen in patients with detectable ctDNA using NGS (HR=0.71 [95% CI: 0.57, 0.89]).18

TP53 co-mutations are markers of aggressive disease and resistance, leading to worse outcomes in EGFR+ mNSCLC19,24-26

Overall survival in patients with TP53 co-mutations27

28%

reduction in risk of death

HR=0.72

(95% CI: 0.53, 0.97)

RYBREVANT® + LAZCLUZE® n=149, osimertinib n=144

PFS subgroup results in patients with TP53 co-mutations

18.2-month mPFS with RYBREVANT® + LAZCLUZE® and 12.9-month mPFS with osimertinib

35%

reduction in risk of progression or death

These analyses are not included in the Prescribing Information for RYBREVANT® or LAZCLUZE®.

These were post hoc exploratory analyses and were not powered to show statistical significance.

1L, first-line; ctDNA, circulating tumor DNA; ddPCR, droplet digital polymerase chain reaction; DNA, deoxyribonucleic acid; ex19del, exon 19 deletion; IV, intravenous; mPFS, median progression-free survival; NGS, next-generation sequencing; PFS, progression-free survival; TP53, tumor protein p53.

For first-line treatment of adult patients with locally advanced or metastatic EGFR+ NSCLC

High and durable responses with a chemo-free combination1,4

Overall response rate1

  • ORR was 78% (95% CI: 74, 82) with RYBREVANT® + LAZCLUZE® (N=429) and 73% (95% CI: 69, 78) with osimertinib (N=429)
    • 73% of patients treated with RYBREVANT® + LAZCLUZE® achieved a PR and 70% of patients treated with osimertinib
    • 5.4% of patients treated with RYBREVANT® + LAZCLUZE® achieved a CR and 3.5% of patients treated with osimertinib

This was a prespecified analysis and was not powered to show statistical significance.

Duration of response1

Median duration of response

Median duration of response graph: RYBREVANT® + LAZCLUZE® 25.8 months vs osimertinib 16.7 months Median duration of response graph: RYBREVANT® + LAZCLUZE® 25.8 months vs osimertinib 16.7 months

This was a prespecified analysis and was not powered to show statistical significance.

~1.5X mDOR with RYBREVANT® + LAZCLUZE®1

CR, complete response; mDOR, median duration of response; ORR, overall response rate; PR, partial response.

CNS Data

NCCN recommends

Amivantamab* (RYBREVANT FASPRO™ or RYBREVANT®)-based regimens†: The only NCCN preferred combination options for brain metastases in patients with EGFR+‡ mNSCLC29§

Overall survival in patients with history of brain metastases3

33%
reduction in
risk of death
HR=0.67

(95% CI: 0.5, 0.9)
RYBREVANT® + LAZCLUZE® n=178, osimertinib n=173

Patients with a history of brain metastases were eligible to enroll in the study (RYBREVANT® + LAZCLUZE® n=180, osimertinib n=186).3
Patients with untreated symptomatic brain metastases and active or prior leptomeningeal disease were excluded from the study.30

This was a prespecified secondary analysis and was not powered to show statistical significance.

Intracranial PFS

Intracranial PFS|| at 36 months in patients with intracranial lesions at baseline3

Intracranial PFS graph: RYBREVANT® + LAZCLUZE® 36% vs osimertinib 18%Intracranial PFS graph: RYBREVANT® + LAZCLUZE® 36% vs osimertinib 18%

This was a prespecified secondary analysis and was not powered to show statistical significance.

2X intracranial PFS at 36 months with RYBREVANT® + LAZCLUZE®3

*Amivantamab includes both amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO™) subcutaneous injection and IV amivantamab-vmjw (RYBREVANT®). Amivantamab and hyaluronidase-lpuj has different dosing and administration instructions compared with IV amivantamab-vmjw.29

†Including but not limited to amivantamab-vmjw + lazertinib.29

‡EGFR exon 19 deletion or exon 21 L858R mutations.29

§See the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for detailed recommendations, including other treatment options.

||Based on median follow-up of 37.8 months.3

For first-line treatment of adult patients with locally advanced or metastatic EGFR+ NSCLC

High intracranial ORR with durable intracranial DOR3,27

Intracranial ORR in patients with intracranial lesions at baseline*

  • Intracranial ORR was 78% (95% CI: 71, 84) with RYBREVANT® + LAZCLUZE® (N=180) and 77% (95% CI: 71, 83) with osimertinib (N=186)3
    • Intracranial CR was 64% with RYBREVANT® + LAZCLUZE® and 59% with osimertinib27
    • Intracranial PR was 14% with RYBREVANT® + LAZCLUZE® and 19% with osimertinib27

This was a prespecified exploratory analysis and was not powered to show statistical significance.

Intracranial DOR in confirmed responders with intracranial lesions at baseline27*†

Median intracranial duration of response

Median intracranial duration of response graph: RYBREVANT® + LAZCLUZE® 35 months vs Osimertinib 25.1 monthsMedian intracranial duration of response graph: RYBREVANT® + LAZCLUZE® 35 months vs Osimertinib 25.1 months

This was a prespecified exploratory analysis and was not powered to show statistical significance.

~1.5X intracranial DOR with RYBREVANT® + LAZCLUZE®27

NCCN PREFERRED THERAPY FOR BRAIN METASTASES

Amivantamab‡ (RYBREVANT FASPRO™ or RYBREVANT®)-based regimens§ including amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO™) + lazertinib (LAZCLUZE®) are the only NCCN preferred combination options for brain metastases in patients with EGFR+|| mNSCLC.29¶

*Based on median follow-up of 37.8 months.3

†Based on subgroup of subjects with history of brain metastasis. CR and PR do not have to be confirmed.27

‡Amivantamab includes both amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO™) subcutaneous injection and IV amivantamab-vmjw (RYBREVANT®). Amivantamab and hyaluronidase-lpuj has different dosing and administration instructions compared with IV amivantamab-vmjw.29

§Including but not limited to amivantamab + lazertinib.29

||EGFR exon 19 deletion or exon 21 L858R mutations.29

See the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for detailed recommendations, including other treatment options.

CNS, central nervous system; DOR, duration of response.

Study Design

For first-line treatment of adult patients with locally advanced or metastatic EGFR+ NSCLC

MARIPOSA: Evaluating the first and only multitargeted combination in first-line EGFR+ mNSCLC vs osimertinib1,4

MARIPOSA is an active-controlled, multicenter, phase 3 trial. Patients with asymptomatic or previously treated and stable intracranial metastases were eligible to enroll. Patients received treatment until disease progression or unacceptable toxicity. The evaluation of efficacy relied upon comparison between RYBREVANT® in combination with LAZCLUZE®, and osimertinib.1,5

Serial brain MRIs were conducted on all patients to assess intracranial progression and response5

  • Serial brain MRIs were performed at baseline and either every 8 weeks for the first 30 months and every 12 weeks thereafter (for patients with a history of brain metastases) or every 24 weeks (for patients without a history)

The largest phase 3 trial and the only one that required serial brain MRIs for all patients, providing accurate detection of CNS progression in patients with 1L EGFR+ disease5,7-17,23*

Serial brain MRIs were
required for all patients

KEY ELIGIBILITY CRITERIA

  • Locally advanced or metastatic NSCLC
  • Treatment-naïve
  • Documented EGFR ex19del or L858R
  • ECOG PS 0 or 1
2:2:1

RANDOMIZATION (N=1,074)

RYBREVANT®
+ LAZCLUZE®
(n=429; open-label)

Osimertinib
(n=429; blinded)

Non-registrational data set

LAZCLUZE®
(n=216; blinded)

PRIMARY ENDPOINT

PFS by BICR per RECIST v1.1

SECONDARY ENDPOINTS

  • OS
  • ORR/DOR
  • Intracranial PFS
  • Safety
Serial brain MRIs were
required for all patients

KEY ELIGIBILITY CRITERIA

  • Locally advanced or metastatic NSCLC
  • Treatment-naïve
  • Documented EGFR ex19del or L858R
  • ECOG PS 0 or 1
2:2:1

RANDOMIZATION (N=1,074)

RYBREVANT®
+ LAZCLUZE®
(n=429; open-label)

Osimertinib
(n=429; blinded)

Non-registrational data set

LAZCLUZE®
(n=216; blinded)

PRIMARY ENDPOINT

PFS by BICR per RECIST v1.1

SECONDARY ENDPOINTS

  • OS
  • ORR/DOR
  • Intracranial PFS
  • Safety

LAZCLUZE® monotherapy arm was included to assess the contribution of the components.5

*MARIPOSA is the largest phase 3 trial that evaluated 1L treatment in patients with EGFR+ mNSCLC as of April 2025.5,7-17

Baseline characteristics were well-balanced across treatment types5

Characteristic
RYBREVANT® + LAZCLUZE® (N=429)
Osimertinib (N=429)
Median age, years (range)
64 (25-88)
63 (28-88)
Female sex, n (%)
275 (64)
251 (59)
Race, n (%)
Asian
250 (58)
251 (59)
White
164 (38)
165 (38)
Other*
15 (3)
13 (3)
ECOG PS 0, n (%)
141 (33)
149 (35)
ECOG PS 1, n (%)
288 (67)
280 (65)
History of smoking, n (%)
130 (30)
134 (31)
History of brain metastases, n (%)
178 (41)
172 (40)
EGFR mutation type, n (%)†
Ex19del
258 (60)
257 (60)
L858R
172 (40)
172 (40)
Adenocarcinoma subtype, n (%)
417 (97)
415 (97)

*Other includes American Indian or Alaska Native, Black, Native Hawaiian or Pacific Islander, multiple, and unknown.

†One patient in the RYBREVANT® + LAZCLUZE® arm had both ex19del and L858R.

BICR, blinded independent central review; MRI, magnetic resonance imaging; RECIST, Response Evaluation Criteria in Solid Tumors.

Safety

Majority of ARs in the MARIPOSA trial were grades 1 and 21

ARs (≥10%) in patients in MARIPOSA1

Adverse reaction
RYBREVANT® + LAZCLUZE® (N=421)
Osimertinib (N=428)
All grades (%)
Grades 3–4 (%)
All grades (%)
Grades 3–4 (%)
Skin and subcutaneous tissue disorders
Rash*
86
26
48
1.2
Nail toxicity*
71
11
34
0.7
Dry skin*
25
1
18
0.2
Pruritus
24
0.5
17
0.2
Injury, poisoning, and procedural complications
Infusion-related reaction†
63
6
0
0
Musculoskeletal and connective tissue disorders
Musculoskeletal pain*
47
2.1
39
1.9
Gastrointestinal disorders
Stomatitis*
43
2.4
27
0.5
Diarrhea*
31
2.6
45
0.9
Constipation
29
0
13
0
Nausea
21
1.2
14
0.2
Vomiting
12
0.5
5
0
Abdominal pain*
11
0
10
0
Hemorrhoids
10
0.2
2.1
0.2
General disorders and administration site conditions
Edema*
43
2.6
8
0
Fatigue*
32
3.8
20
1.9
Pyrexia
12
0
9
0
Vascular disorders
Venous thromboembolism*
36
11
8
2.8
Hemorrhage*
25
1
13
1.2
Nervous system disorders
Paresthesia*
35
1.7
10
0.2
Dizziness*
14
0
10
0
Headache*
13
0.2
13
0
Infections and infestations
COVID-19
26
1.7
24
1.4
Conjunctivitis
11
0.2
1.6
0
Metabolism and nutrition disorders
Decreased appetite
24
1
18
1.4
Respiratory, thoracic, and mediastinal disorders
Cough*
19
0
23
0
Dyspnea*
14
1.7
17
3.5
Eye disorders
Ocular toxicity*
16
0.7
7
0
Psychiatric disorders
Insomnia
10
0
11
0

*Grouped terms.

†Applicable for RYBREVANT® only.

  • Serious ARs occurred in 49% of patients with RYBREVANT® + LAZCLUZE® and 33% with osimertinib1,5
  • Serious ARs in ≥2% of patients included VTE (11%), pneumonia (4%), rash (2.9%), ILD/pneumonitis (2.9%), COVID-19 (2.4%), pleural effusion (2.1%), and IRR (2.1%)1
  • Fatal ARs occurred in 7% of patients who received RYBREVANT® + LAZCLUZE® and 7% with osimertinib1,5
  • The most common ARs (≥20%) were rash, nail toxicity, IRR, musculoskeletal pain, stomatitis, edema, VTE, paresthesia, fatigue, diarrhea, constipation, COVID-19, hemorrhage, dry skin, decreased appetite, pruritus, and nausea1
  • Clinically relevant ARs (<10%) in patients who received RYBREVANT® + LAZCLUZE® included skin ulcer (5.2%) and ILD/pneumonitis (3.1%)1,27

Learn about the safety profile of RYBREVANT FASPRO™

Learn more

Select laboratory abnormalities that worsened from baseline (≥20%) in MARIPOSA1*

Laboratory abnormality
RYBREVANT® + LAZCLUZE® (N=421)
Osimertinib (N=428)
All grades
(%)
Grades 3-4
(%)
All grades
(%)
Grades 3-4
(%)
Chemistry
Decreased albumin
89
8
22
0.2
Increased alanine aminotransferase
65
7
29
2.6
Increased aspartate aminotransferase
52
3.8
36
1.9
Increased alkaline phosphatase
45
0.5
15
0.5
Decreased calcium (corrected)
41
1.4
27
0.7
Increased gamma-glutamyl transferase
39
2.6
24
1.9
Decreased sodium
38
7
35
5
Decreased potassium
30
5
15
1.2
Increased creatinine
26
0.7
35
0.7
Decreased magnesium
25
0.7
10
0.2
Increased magnesium
12
2.6
20
4.8
Hematology
Decreased platelet count
52
0.7
57
1.4
Decreased hemoglobin
47
3.8
56
1.9
Decreased white blood cell
38
1
66
0.7
Decreased neutrophils
15
1.4
33
1.4

*The denominator used to calculate the rate is the number of patients with a baseline value and at least one post-treatment value for the specific lab test.

The most common grade 3 or 4 laboratory abnormalities (≥2%) were decreased albumin, decreased sodium, increased alanine aminotransferase, decreased potassium, decreased hemoglobin, increased aspartate aminotransferase, increased gamma-glutamyl transferase, and increased magnesium.1

Key ARs occurred more frequently during the first 4 months and declined over the next 4 months27*
Key adverse reactions analysis displaying decreases in reactions in every grouping in months 5-8Key adverse reactions analysis displaying decreases in reactions in every grouping in months 5-8

This was a post hoc exploratory analysis and is not included in the Prescribing Information for RYBREVANT® or LAZCLUZE®.

*Patients with PFS events or who were censored in the first 4 months were excluded from this analysis.

IIR rates in the MARIPOSA clinical trial IIR rates in the MARIPOSA clinical trial
  • 92.3% of IRRs were grades 1 and 227
  • Median time to onset of first IRR was 1 hour (range, 0.05–52.5 hours)27
  • Monitor patients for any signs and symptoms of IRRs during RYBREVANT® infusion in a setting where cardiopulmonary resuscitation medication and equipment are available. Interrupt infusion if IRR is suspected. Reduce the infusion rate or permanently discontinue RYBREVANT® based on severity31
  • If an anaphylactic reaction occurs, permanently discontinue RYBREVANT®31
  • Signs and symptoms of IRR include dyspnea, flushing, fever, chills, nausea, chest discomfort, hypotension, and vomiting31

Prophylaxis may reduce the risk of IRRs, dermatologic ARs, and VTE

Learn more

AR, adverse reaction; ILD, interstitial lung disease; IRR, infusion-related reaction; VTE, venous thromboembolism.

Dose Modifications and Discontinuation Rates

Adaptable dosing is available to help your patients manage ARs and stay on treatment27*

Most patients used dose modification to continue treatment with RYBREVANT® + LAZCLUZE®.1,4

Median duration of treatment including dose modifications3

Discontinuation rates due to ARs graph: RYBREVANT® + LAZCLUZE® 27 months vs Osimertinib 22.4 monthsDiscontinuation rates due to ARs graph: RYBREVANT® + LAZCLUZE® 27 months vs Osimertinib 22.4 months

*Certain types and severity of ARs require discontinuation after first occurrence.1

Dose interruptions did not compromise results: Median PFS was similar after 4 months, regardless of whether patients had dose interruptions27,32*†

With dose interruptions in the first 4 months:

27.5 months

(95% Cl: 20.3, NE) (N=188)

Without dose interruptions in the first 4 months:

25.7 months

(95% Cl: 22.2, NE) (N=190)

  • In this analysis, dose interruption was defined as a skipped dose that is not made up; this population may also include patients who had a dose reduction or drug discontinuation32

This was a post hoc exploratory analysis from MARIPOSA and is not included in the Prescribing Information for RYBREVANT® or LAZCLUZE®.

*In this descriptive analysis of PFS, the hazard ratio by multivariable analysis (via multivariate Cox proportional hazards model, only included patients still at risk of PFS at 4 months) adjusted for age, ECOG PS, EGFR mutation type, Asian race, and history of brain metastases was 1.06 (95% CI: 0.73, 1.44).32

†To minimize bias, outcomes (such as progression events or deaths that could occur before interruptions leading to outcomes-based selection bias) were evaluated after the first 4 months. Patients who discontinued the study, had disease progression, or died in the first 4 months were not evaluated, as they were not in the study by the cutoff timepoint (and the outcome event may have occurred prior to the interruption).32

Dose modifications1,4

  • Dose interruptions due to an AR occurred in 88% of patients with RYBREVANT® and 72% of patients with LAZCLUZE®
  • Dose reductions due to an AR occurred in 46% of patients with RYBREVANT® and 42% of patients with LAZCLUZE®

Discontinuation rates

  • The rate of discontinuations of all agents due to treatment-related ARs was 10% for RYBREVANT® + LAZCLUZE®5
  • Permanent discontinuation of RYBREVANT® due to an AR occurred in 34% of patients1
  • Permanent discontinuation of LAZCLUZE® due to an AR occurred in 21% of patients4

Learn more about available adaptable dosing

Learn more

2L, second-line.

References:

  1. RYBREVANT FASPRO™ [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  2. Yang JC-H, Kim YJ, Lee S-H, et al. Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced NSCLC: final overall survival from the phase 3 MARIPOSA study. Presented at: European Lung Cancer Congress; March 26-29, 2025; Paris, France.
  3. Yang JC-H, Lu S, Hayashi H, et al; MARIPOSA Investigators. Overall survival with amivantamab–lazertinib in EGFR-mutated advanced NSCLC. N Engl J Med. 2025;393(17):1681-1693. doi:10.1056/NEJMoa2503001
  4. LAZCLUZE® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  5. Cho BC, Lu S, Felip E, et al; MARIPOSA Investigators. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2024;391(16):1486-1498. doi:10.1056/NEJMoa2403614
  6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.7.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed August 7, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  7. Yang JC-H, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830-838. doi:10/1016/S1470-2045(15)00026-1
  8. Wu Y-L, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454-1466. doi:10.1016/S1470-2045(17)30608-3
  9. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-246. doi:10.1016/S1470-2045(11)70393-X
  10. Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655-1669. doi:10.1016/S1470-2045(19)30634-5
  11. Kawashima Y, Fukuhara T, Saito H, et al. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Respir Med. 2022;10(1):72-82. doi:10.1016/S2213-2600(21)00166-1
  12. Douillard J-Y, Ostoros G, Cobo M, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer. 2014;110(1):55-62. doi:10.1038/bjc.2013.721
  13. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957. doi:10.1056/NEJMoa0810699
  14. Soria J-C, Ohe Y, Vansteenkiste J, et al; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378(2):113-125. doi:10.1056/NEJMoa1713137
  15. Planchard D, Jänne PA, Cheng Y, et al; FLAURA2 Investigators. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389(21):1935-1948. doi:10.1056/NEJMoa2306434
  16. Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2017;376(7):629-640. doi:10.1056/NEJMoa1612674
  17. Goldberg SB, Pulla MP, Lisberg AE, et al. 123TiP: TROPION-Lung14: a phase III study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC). J Thorac Oncol. 2025;20(3)(suppl 1):S86-S87. doi:10.1016/S1556-0864(25)00318-1
  18. Felip E, Cho BC, Gutiérrez V, et al. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Ann Oncol. 2024;35(9):805-816. doi:10.1016/j.annonc.2024.05.541
  19. Roeper J, Falk M, Chalaris-Rißmann A, et al. TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: a strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC. Oncotarget. 2020;11(3):250-264. doi:10.18632/oncotarget.27430
  20. Taniguchi Y, Tamiya A, Nakahama K, et al. Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors. Oncol Lett. 2017;14(6):7589-7596. doi:10.3892/ol.2017.7125
  21. Choi MG, Choi C-M, Lee DH, et al. Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study. Transl Lung Cancer Res. 2021;10(6):2551-2561. doi:10.21037/tlcr-21-206
  22. Jänne PA, Kobayashi K, Robichaux J, et al. Abstract CT017: FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexed. Cancer Res. 2024;84(S7):CT017. doi:10.1158/1538-7445.AM2024-CT017
  23. Cho BC, Lu S, Felip E, et al; MARIPOSA Investigators. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. Supplementary Appendix. N Engl J Med. 2024;391(16):1486-1498. doi:10.1056/NEJMoa2403614
  24. Canale M, Andrikou K, Priano I, et al. The role of TP53 mutations in EGFR-mutated non-small-cell lung cancer: clinical significance and implications for therapy. Cancers (Basel). 2022;14(5):1143. doi:10.3390/cancers14051143
  25. Liu S-Y, Zhou J-Y, Li W-F, et al. Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphism. Clin Transl Med. 2020:10(1):337-345. doi:10.1002/ctm2.12
  26. Gu W, Liu P, Tang J, et al. The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs. Front Oncol. 2024;13:1288468. doi:10.3389/fonc.2023.1288468
  27. Data on file. Janssen Biotech, Inc.
  28. Felip E, Cho BC, Gutiérrez V, et al. Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: a secondary analysis from the phase 3 MARIPOSA study. Presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2024; Chicago, Illinois.
  29. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers V.3.2026 © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed August 17, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  30. Cho BC, Lu S, Felip E, et al; MARIPOSA Investigators. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. Protocol. N Engl J Med. 2024;391(16):1486-1498. doi:10.1056/NEJMoa2403614
  31. RYBREVANT® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  32. Campelo MRG, Cho BC, Girard N, et al. Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: exploratory analyses from the MARIPOSA study. Presented at: European Lung Cancer Congress; March 20-23, 2024; Prague, Czech Republic.